Abstract
Given that MS is a complex, multisystem disease which may cause difficult symptoms in many different systems, the approach to symptom control should be led and coordinated by a physician with a specialist interest in MS. Over the course of the disease, a variable degree of input is likely to be required from primary care physicians as well as specialists in a variety of medical specialities, including, although not limited to, neurology, neurorehabilitation, and palliative care. The role of health professionals in disciplines allied to medicine should not be underestimated and careful attention must be given to patient preference. The needs of caregivers should also be respected and facilitated. In the absence of an available cure for MS, research into improved symptom management should be supported and must include systematic, well-designed clinical trials to evaluate treatments as they emerge.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Thompson AJ. Neurorehabilitation in multiple sclerosis: foundations, facts and fiction. Curr Opin Neurol. 2005;18(3):267–71.
The UN standard rules on the equalization of opportunities for persons with disabilities. Geneva: World Health Organisation; 2001. p. 290.
Holper L, et al. Characterization of functioning in multiple sclerosis using the ICF. J Neurol. 2010;257(1):103–13.
Kesselring J, et al. Developing the ICF Core Sets for multiple sclerosis to specify functioning. Mult Scler. 2008;14(2):252–4.
National Institute for Clinical Excellence (NICE). Guidance for the management of MS. In: Multiple Sclerosis: national clinical guideline for diagnosis and management in primary and secondary care. London: NICE; 2003.
Multiple Sclerosis International Federation (MSIF). Principles to promote the quality of life of people with multiple sclerosis. London: Multiple Sclerosis International Federation; 2005.
Platform ME, editor. Recommendations on rehabilitation services for persons with multiple sclerosis in Europe. Genoa: Associazione Italiana Sclerosi Multipla; 2004.
Miller D, Rudick RA, Hutchinson M. Patient-centered outcomes: translating clinical efficacy into benefits on health-related quality of life. Neurology. 2010;74 Suppl 3:S24–35.
Thompson AJ, Toosy AT, Ciccarelli O. Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions. Lancet Neurol. 2010;9(12):1182–99.
Lance JW. Symposium synopsis. in Spasticity: disordered motor control. Chicago: Year Book; 1980.
Pandyan AD, et al. Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disabil Rehabil. 2005;27(1–2):2–6.
Rizzo MA, et al. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004;10(5):589–95.
Paisley S, et al. Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic review. Mult Scler. 2002;8(4):319–29.
Paty DW, Ebers GC. Clinical features. In: Paty DW, Ebers GC, editors. Multiple sclerosis. Philadelphia: F. A. Davis; 1998. p. 135–92.
Francis HP, et al. Does reducing spasticity translate into functional benefit? An exploratory meta-analysis. J Neurol Neurosurg Psychiatry. 2004;75(11):1547–51.
Stevenson VL. Oral medication. In: Stevenson VL, Jarrett L, editors. Spasticity management: a practical multidisciplinary guide. London: Informa Healthcare; 2006. p. 59–70.
Paty DW, Hashimoto SA, Ebers GC. Management of multiple sclerosis and interpretation of clinical trials. In: Paty DW, Ebers GC, editors. Multiple sclerosis. Philadelphia: F. A. Davis; 1998. p. 427–519.
Rosche J, et al. The effects of therapy on spasticity utilizing a motorized exercise-cycle. Spinal Cord. 1997;35(3):176–8.
Kakebeeke TH, Lechner HE, Knapp PA. The effect of passive cycling movements on spasticity after spinal cord injury: preliminary results. Spinal Cord. 2005;43(8):483–8.
Nuyens GE, et al. Reduction of spastic hypertonia during repeated passive knee movements in stroke patients. Arch Phys Med Rehabil. 2002;83(7):930–5.
Schmit BD, Dewald JP, Rymer WZ. Stretch reflex adaptation in elbow flexors during repeated passive movements in unilateral brain-injured patients. Arch Phys Med Rehabil. 2000;81(3):269–78.
Katalinic OM, et al. Stretch for the treatment and prevention of contractures. Cochrane Database Syst Rev. 2010;(9):CD007455.
Gao F, et al. Effects of repeated ankle stretching on calf muscle-tendon and ankle biomechanical properties in stroke survivors. Clin Biomech (Bristol, Avon). 2011;26(5):516–22.
Katalinic OM, Harvey LA, Herbert RD. Effectiveness of stretch for the treatment and prevention of contractures in people with neurological conditions: a systematic review. Phys Ther. 2011;91(1):11–24.
White LJ, et al. Resistance training improves strength and functional capacity in persons with multiple sclerosis. Mult Scler. 2004;10(6):668–74.
Odeen I, Knutsson E. Evaluation of the effects of muscle stretch and weight load in patients with spastic paraplegia. Scand J Rehabil Med. 1981;13(4):117–21.
Bohannon RW. Tilt table standing for reducing spasticity after spinal cord injury. Arch Phys Med Rehabil. 1993;74(10):1121–2.
Rietberg MB, et al. Exercise therapy for multiple sclerosis. Cochrane Database Syst Rev. 2005;(1):CD003980.
Lockley LJ, Buchanan K. Physical management of spasticity. In: Stevenson VL, Jarrett L, editors. Spasticity management: a practical multidisciplinary guide. London: Informa Healthcare; 2006. p. 37–58.
Stevenson VL. Rehabilitation in practice: spasticity management. Clin Rehabil. 2010;24(4):293–304.
Dalgas U, et al. Muscle fiber size increases following resistance training in multiple sclerosis. Mult Scler. 2010;16(11):1367–76.
Dalgas U, et al. Fatigue, mood and quality of life improve in MS patients after progressive resistance training. Mult Scler. 2010;16(4):480–90.
Golzari Z, et al. Combined exercise training reduces IFN-gamma and IL-17 levels in the plasma and the supernatant of peripheral blood mononuclear cells in women with multiple sclerosis. Int Immunopharmacol. 2010;10(11):1415–9.
Mori F, et al. Transcranial magnetic stimulation primes the effects of exercise therapy in multiple sclerosis. J Neurol. 2011;258(7):1281–7.
Centonze D, et al. Repetitive transcranial magnetic stimulation of the motor cortex ameliorates spasticity in multiple sclerosis. Neurology. 2007;68(13):1045–50.
Mori F, et al. Effects of intermittent theta burst stimulation on spasticity in patients with multiple sclerosis. Eur J Neurol. 2010;17(2):295–300.
Nielsen JF, Sinkjaer T, Jakobsen J. Treatment of spasticity with repetitive magnetic stimulation; a double-blind placebo-controlled study. Mult Scler. 1996;2(5):227–32.
Butefisch CM, et al. Mechanisms of use-dependent plasticity in the human motor cortex. Proc Natl Acad Sci USA. 2000;97(7):3661–5.
Holtmaat A, Svoboda K. Experience-dependent structural synaptic plasticity in the mammalian brain. Nat Rev Neurosci. 2009;10(9):647–58.
Cooke SF, Bliss TV. Plasticity in the human central nervous system. Brain. 2006;129(Pt 7):1659–73.
Ratchford JN, et al. A pilot study of functional electrical stimulation cycling in progressive multiple sclerosis. NeuroRehabilitation. 2010;27(2):121–8.
Barrett CL, et al. A randomized trial to investigate the effects of functional electrical stimulation and therapeutic exercise on walking performance for people with multiple sclerosis. Mult Scler. 2009;15(4):493–504.
Everaert DG, et al. Does functional electrical stimulation for foot drop strengthen corticospinal connections? Neurorehabil Neural Repair. 2010;24(2):168–77.
Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev. 2003;(4):CD001332.
Hobart JC, et al. Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. Lancet Neurol. 2007;6(12):1094–105.
Hattab JR. Review of European clinical trials with baclofen. In: Feldman RG, Young RR, Koella WP, editors. Spasticity: disordered motor control. Chicago: Year Book; 1980. p. 71–85.
A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group. Neurology. 1994;44(11 Suppl 9):S70–8.
Nance PW, et al. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group. Neurology. 1994;44(11 Suppl 9):S44–51; discussion S51–2.
Smith C, et al. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. Neurology. 1994;44(11 Suppl 9):S34–42; discussion S42–3.
Groves L, Shellenberger MK, Davis CS. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam. Adv Ther. 1998;15(4):241–51.
Wagstaff AJ, Bryson HM. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 1997;53(3):435–52.
Krause T, et al. Dantrolene – a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 2004;59(4):364–73.
Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess. 2003;7(40):iii, ix–x, 1–111.
Mueller ME, et al. Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Arch Phys Med Rehabil. 1997;78(5):521–4.
Cutter NC, et al. Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. Arch Phys Med Rehabil. 2000;81(2):164–9.
Formica A, et al. Gabapentin for spasticity: a randomized, double-blind, placebo-controlled trial. Med Clin (Barc). 2005;124(3):81–5.
Fink K, et al. Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology. 2002;42(2):229–36.
Bradley LJ, Kirker SG. Pregabalin in the treatment of spasticity: a retrospective case series. Disabil Rehabil. 2008;30(16):1230–2.
Rigo JM, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol. 2002;136(5):659–72.
Bedlack RS, et al. Open-label pilot trial of levetiracetam for cramps and spasticity in patients with motor neuron disease. Amyotroph Lateral Scler. 2009;10(4):210–5.
Ruegg SJ, Steck AJ, Fuhr P. Levetiracetam improves paroxysmal symptoms in a patient with stiff-person syndrome. Neurology. 2004;62(2):338.
Lashch N, Avakian GN. The use of midokalm in patients with multiple sclerosis. Zh Nevrol Psikhiatr Im SS Korsakova. 2000;100(6):24–8.
Stamenova P, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke. Eur J Neurol. 2005;12(6):453–61.
Bresolin N, Zucca C, Pecori A. Efficacy and tolerability of eperisone in patients with spastic palsy: a cross-over, placebo-controlled dose-ranging trial. Eur Rev Med Pharmacol Sci. 2009;13(5):365–70.
Bresolin N, Zucca C, Pecori A. Efficacy and tolerability of eperisone and baclofen in spastic palsy: a double-blind randomized trial. Adv Ther. 2009;26(5):563–73.
Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction. 1996;91(11):1585–614.
Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964;86:1646–7.
Tsou K, et al. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 1998;83(2):393–411.
Herkenham M, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA. 1990;87(5):1932–6.
Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev. 2003;83(3):1017–66.
Van Sickle MD, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science. 2005;310(5746):329–32.
Skaper SD, et al. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci USA. 1996;93(9):3984–9.
Alger BE. Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Prog Neurobiol. 2002;68(4):247–86.
Kreitzer AC, Regehr WG. Retrograde signaling by endocannabinoids. Curr Opin Neurobiol. 2002;12(3):324–30.
Berrendero F, et al. Changes in cannabinoid CB(1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse. 2001;41(3):195–202.
Baker D, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature. 2000;404(6773):84–7.
Baker D, et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 2001;15(2):300–2.
Baker D, Pryce G. The endocannabinoid system and multiple sclerosis. Curr Pharm Des. 2008;14(23):2326–36.
Chong MS, et al. Cannabis use in patients with multiple sclerosis. Mult Scler. 2006;12(5):646–51.
Clark AJ, et al. Patterns of cannabis use among patients with multiple sclerosis. Neurology. 2004;62(11):2098–100.
Campbell FA, et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ. 2001;323(7303):13–6.
Zajicek JP, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry. 2005;76(12):1664–9.
Malfitano AM, Proto MC, Bifulco M. Cannabinoids in the management of spasticity associated with multiple sclerosis. Neuropsychiatr Dis Treat. 2008;4(5):847–53.
Lakhan SE, Rowland M. Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review. BMC Neurol. 2009;9:59.
Smith PF. New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids. Ther Clin Risk Manag. 2010;6:59–63.
Wade DT, et al. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler. 2010;16(6):707–14.
Hobart JC, et al. Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88). Brain. 2006;129(Pt 1):224–34.
Zajicek JP, Apostu VI. Role of cannabinoids in multiple sclerosis. CNS Drugs. 2011;25(3):187–201.
Honarmand K, et al. Effects of cannabis on cognitive function in patients with multiple sclerosis. Neurology. 2011;76(13):1153–60.
Dolly JO, Aoki KR. The structure and mode of action of different botulinum toxins. Eur J Neurol. 2006;13 Suppl 4:1–9.
Ward AB. Spasticity treatment with botulinum toxins. J Neural Transm. 2008;115(4):607–16.
Kabus C, et al. Botulinum toxin in patients with multiple sclerosis. J Neurol. 2006;253 Suppl 1:I26–8.
Habek M, et al. The place of the botulinum toxin in the management of multiple sclerosis. Clin Neurol Neurosurg. 2010;112(7):592–6.
Giovannelli M, et al. Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clin Rehabil. 2007;21(4):331–7.
Borg J, et al. Rationale and design of a multicentre, double-blind, prospective, randomized, European and Canadian study: evaluating patient outcomes and costs of managing adults with post-stroke focal spasticity. J Rehabil Med. 2011;43(1):15–22.
Burbaud P, et al. Botulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness study. J Neurol. 2011;258(9):1670–5.
Elovic EP, et al. Chemodenervation and nerve blocks in the diagnosis and management of spasticity and muscle overactivity. PM R. 2009;1(9):842–51.
Yelnik AP, et al. How to clinically assess and treat muscle overactivity in spastic paresis. J Rehabil Med. 2010;42(9):801–7.
Bensmail D, et al. Effect of intrathecal baclofen on sleep and respiratory function in patients with spasticity. Neurology. 2006;67(8):1432–6.
Boviatsis EJ, et al. Functional outcome of intrathecal baclofen administration for severe spasticity. Clin Neurol Neurosurg. 2005;107(4):289–95.
Zahavi A, et al. Long term effect (more than five years) of intrathecal baclofen on impairment, disability, and quality of life in patients with severe spasticity of spinal origin. J Neurol Neurosurg Psychiatry. 2004;75(11):1553–7.
Rekand T, Gronning M. Treatment of spasticity related to multiple sclerosis with intrathecal baclofen: a long-term follow-up. J Rehabil Med. 2011;43(6):511–4.
Schuele SU, et al. Incidence of seizures in patients with multiple sclerosis treated with intrathecal baclofen. Neurology. 2005;64(6):1086–7.
Cooper JA, Ridley B. Response of intrathecal baclofen resistance to dose reduction. Neurology. 2006;67(8):1495–6.
Kelly RE, Gautier Smith PC. Intrathecal phenol in the treatment of reflex spasms and spasticity. Lancet. 1959;274(7112):1102–5.
Maher RM. Relief of pain in incurable cancer. Lancet. 1955;265(6853):18–20.
Jarrett L, Nandi P, Thompson AJ. Managing severe lower limb spasticity in multiple sclerosis: does intrathecal phenol have a role? J Neurol Neurosurg Psychiatry. 2002;73(6):705–9.
Boop FA. Evolution of the neurosurgical management of spasticity. J Child Neurol. 2001;16(1):54–7.
Foerster O. On the indications and results of the excision of posterior spinal nerve roots in men. Surg Gynecol Obstet. 1913;16:463–74.
Sherrington C. The integrative action of the central nervous system. London: Archibald Constable; 1906.
Gros C, et al. La radicotomie selective posterieure dans le traitement neurochirurgical de l’hypertonie pyramidale. Neurochirurgie. 1967;13:505–18.
Salame K, et al. Surgical treatment of spasticity by selective posterior rhizotomy: 30 years experience. Isr Med Assoc J. 2003;5(8):543–6.
Maarrawi J, et al. Long-term functional results of selective peripheral neurotomy for the treatment of spastic upper limb: prospective study in 31 patients. J Neurosurg. 2006;104(2):215–25.
Sindou M, Mertens P. Selective neurotomy of the tibial nerve for treatment of the spastic foot. Neurosurgery. 1988;23(6):738–44.
O’Connor AB, et al. Pain associated with multiple sclerosis: systematic review and proposed classification. Pain. 2008;137(1):96–111.
Hirsh AT, et al. Prevalence and impact of pain in multiple sclerosis: physical and psychologic contributors. Arch Phys Med Rehabil. 2009;90(4):646–51.
Brichetto G, et al. Symptomatic medication use in multiple sclerosis. Mult Scler. 2003;9(5):458–60.
Moulin DE, Foley KM, Ebers GC. Pain syndromes in multiple sclerosis. Neurology. 1988;38(12):1830–4.
Osterberg A, Boivie J, Thuomas KA. Central pain in multiple sclerosis – prevalence and clinical characteristics. Eur J Pain. 2005;9(5):531–42.
Vermote R, Ketelaer P, Carton H. Pain in multiple sclerosis patients. A prospective study using the Mc Gill Pain Questionnaire. Clin Neurol Neurosurg. 1986;88(2):87–93.
Boneschi FM, et al. Lifetime and actual prevalence of pain and headache in multiple sclerosis. Mult Scler. 2008;14(4):514–21.
Solaro C, et al. The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. Neurology. 2004;63(5):919–21.
Hadjimichael O, et al. Persistent pain and uncomfortable sensations in persons with multiple sclerosis. Pain. 2007;127(1–2):35–41.
Ehde DM, et al. Chronic pain in a large community sample of persons with multiple sclerosis. Mult Scler. 2003;9(6):605–11.
Brochet B, et al. Pain and quality of life in the early stages after multiple sclerosis diagnosis: a 2-year longitudinal study. Clin J Pain. 2009;25(3):211–7.
Svendsen KB, et al. Pain in patients with multiple sclerosis: a population-based study. Arch Neurol. 2003;60(8):1089–94.
Putzki N, Katsarava Z. Headache in multiple sclerosis. Curr Pain Headache Rep. 2010;14(4):316–20.
Kister I, et al. Tension-type headache and migraine in multiple sclerosis. Curr Pain Headache Rep. 2010;14(6):441–8.
Welch KM, et al. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache. 2001;41(7):629–37.
Knight YE, Goadsby PJ. The periaqueductal grey matter modulates trigeminovascular input: a role in migraine? Neuroscience. 2001;106(4):793–800.
Pollmann W, Feneberg W. Current management of pain associated with multiple sclerosis. CNS Drugs. 2008;22(4):291–324.
Treede RD, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70(18):1630–5.
Grasso MG, et al. Pain in multiple sclerosis: a clinical and instrumental approach. Mult Scler. 2008;14(4):506–13.
Attal N, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol. 2006;13(11):1153–69.
Tan T, et al. Pharmacological management of neuropathic pain in non-specialist settings: summary of NICE guidance. BMJ. 2010;340:c1079.
Rahn EJ, Hohmann AG. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics. 2009;6(4):713–37.
Iskedjian M, et al. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin. 2007;23(1):17–24.
Karst M, Wippermann S, Ahrens J. Role of cannabinoids in the treatment of pain and (painful) spasticity. Drugs. 2010;70(18):2409–38.
Rowbotham MC, et al. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med. 2003;348(13):1223–32.
Breuer B, et al. A randomized, double-blind, placebo-controlled, two-period, crossover, pilot trial of lamotrigine in patients with central pain due to multiple sclerosis. Clin Ther. 2007;29(9):2022–30.
Kalman S, et al. Morphine responsiveness in a group of well-defined multiple sclerosis patients: a study with i.v. morphine. Eur J Pain. 2002;6(1):69–80.
Chitsaz A, et al. Sensory complaints of the upper extremities in multiple sclerosis: relative efficacy of nortriptyline and transcutaneous electrical nerve stimulation. Clin J Pain. 2009;25(4):281–5.
Kumar K, Hunter G, Demeria D. Spinal cord stimulation in treatment of chronic benign pain: challenges in treatment planning and present status, a 22-year experience. Neurosurgery. 2006;58(3):481–96; discussion 481–96.
Osenbach RK. Motor cortex stimulation for intractable pain. Neurosurg Focus. 2006;21(6):E7.
Levy R, Deer TR, Henderson J. Intracranial neurostimulation for pain control: a review. Pain Physician. 2010;13(2):157–65.
Patwardhan RV, et al. Neurosurgical treatment of multiple sclerosis. Neurol Res. 2006;28(3):320–5.
Sadiq SA, Poopatana CA. Intrathecal baclofen and morphine in multiple sclerosis patients with severe pain and spasticity. J Neurol. 2007;254(10):1464–5.
Dahm PO, et al. Long-term intrathecal (i.t.) infusion of bupivacaine relieved intractable pain and spasticity in a patient with multiple sclerosis. Eur J Pain. 1998;2(1):81–5.
Solaro C, Tanganelli P. Tiagabine for treating painful tonic spasms in multiple sclerosis: a pilot study. J Neurol Neurosurg Psychiatry. 2004;75(2):341.
Hawker K, Frohman E, Racke M. Levetiracetam for phasic spasticity in multiple sclerosis. Arch Neurol. 2003;60(12):1772–4.
Solaro C, et al. Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis. Mult Scler. 2000;6(3):192–3.
Morgan JC, Hess DC, Sethi KD. Botulinum toxin treatment of painful tonic spasms in multiple sclerosis. Neurology. 2004;62(11):2143; author reply 2143.
Restivo DA, et al. Botulinum toxin treatment of painful tonic spasms in multiple sclerosis. Neurology. 2003;61(5):719–20.
Sakurai M, Kanazawa I. Positive symptoms in multiple sclerosis: their treatment with sodium channel blockers, lidocaine and mexiletine. J Neurol Sci. 1999;162(2):162–8.
Putzki N, et al. Prevalence of migraine, tension-type headache and trigeminal neuralgia in multiple sclerosis. Eur J Neurol. 2009;16(2):262–7.
Rushton JG, Olafson RA. Trigeminal neuralgia associated with multiple sclerosis: report of 35 cases. Arch Neurol. 1965;13(4):383–6.
Love S, Gradidge T, Coakham HB. Trigeminal neuralgia due to multiple sclerosis: ultrastructural findings in trigeminal rhizotomy specimens. Neuropathol Appl Neurobiol. 2001;27(3):238–44.
Love S, Coakham HB. Trigeminal neuralgia: pathology and pathogenesis. Brain. 2001;124(Pt 12):2347–60.
Cruccu G, et al. Trigeminal neuralgia and pain related to multiple sclerosis. Pain. 2009;143(3):186–91.
Espir ML, Millac P. Treatment of paroxysmal disorders in multiple sclerosis with carbamazepine (Tegretol). J Neurol Neurosurg Psychiatry. 1970;33(4):528–31.
Solaro C, et al. Antiepileptic medications in multiple sclerosis: adverse effects in a three-year follow-up study. Neurol Sci. 2005;25(6):307–10.
Ramsaransing G, Zwanikken C, De Keyser J. Worsening of symptoms of multiple sclerosis associated with carbamazepine. BMJ. 2000;320(7242):1113.
Lunardi G, et al. Clinical effectiveness of lamotrigine and plasma levels in essential and symptomatic trigeminal neuralgia. Neurology. 1997;48(6):1714–7.
Leandri M, et al. Lamotrigine in trigeminal neuralgia secondary to multiple sclerosis. J Neurol. 2000;247(7):556–8.
Solaro C, et al. Low-dose gabapentin combined with either lamotrigine or carbamazepine can be useful therapies for trigeminal neuralgia in multiple sclerosis. Eur Neurol. 2000;44(1):45–8.
Khan OA. Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients. Neurology. 1998;51(2):611–4.
Solaro C, et al. An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. Neurology. 1998;51(2):609–11.
Zvartau-Hind M, et al. Topiramate relieves refractory trigeminal neuralgia in MS patients. Neurology. 2000;55(10):1587–8.
Solaro C, et al. Topiramate relieves idiopathic and symptomatic trigeminal neuralgia. J Pain Symptom Manage. 2001;21(5):367–8.
DMKG study group. Misoprostol in the treatment of trigeminal neuralgia associated with multiple sclerosis. J Neurol. 2003;250(5):542–5.
Reder AT, Arnason BG. Trigeminal neuralgia in multiple sclerosis relieved by a prostaglandin E analogue. Neurology. 1995;45(6):1097–100.
Zakrzewska JM, et al. Patient reports of satisfaction after microvascular decompression and partial sensory rhizotomy for trigeminal neuralgia. Neurosurgery. 2005;56(6):1304–11; discussion 1311–2.
Brisman R. Trigeminal neuralgia and multiple sclerosis. Arch Neurol. 1987;44(4):379–81.
Eldridge PR, et al. Microvascular decompression for trigeminal neuralgia in patients with multiple sclerosis. Stereotact Funct Neurosurg. 2003;81(1–4):57–64.
Athanasiou TC, et al. Some patients with multiple sclerosis have neurovascular compression causing their trigeminal neuralgia and can be treated effectively with MVD: report of five cases. Br J Neurosurg. 2005;19(6):463–8.
Broggi G, et al. Operative findings and outcomes of microvascular decompression for trigeminal neuralgia in 35 patients affected by multiple sclerosis. Neurosurgery. 2004;55(4):830–8; discussion 838–9.
Broggi G, et al. Role of microvascular decompression in trigeminal neuralgia and multiple sclerosis. Lancet. 1999;354(9193):1878–9.
Broggi G, et al. Microvascular decompression for trigeminal neuralgia: comments on a series of 250 cases, including 10 patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2000;68(1):59–64.
Sandell T, Eide PK. The effect of microvascular decompression in patients with multiple sclerosis and trigeminal neuralgia. Neurosurgery. 2010;67(3):749–53; discussion 753–4.
Zakrzewska JM, McMillan R. Trigeminal neuralgia: the diagnosis and management of this excruciating and poorly understood facial pain. Postgrad Med J. 2011;87(1028):410–6.
Harries AM, Mitchell RD. Percutaneous glycerol rhizotomy for trigeminal neuralgia: safety and efficacy of repeat procedures. Br J Neurosurg. 2011;25(2):268–72.
Pickett GE, Bisnaire D, Ferguson GG. Percutaneous retrogasserian glycerol rhizotomy in the treatment of tic douloureux associated with multiple sclerosis. Neurosurgery. 2005;56(3):537–45; discussion 537–45.
Kanpolat Y, et al. Percutaneous controlled radiofrequency rhizotomy in the management of patients with trigeminal neuralgia due to multiple sclerosis. Acta Neurochir (Wien). 2000;142(6):685–9; discussion 689–90.
Zorro O, et al. Gamma knife radiosurgery for multiple sclerosis-related trigeminal neuralgia. Neurology. 2009;73(14):1149–54.
Verheul JB, et al. Gamma Knife surgery for trigeminal neuralgia: a review of 450 consecutive cases. J Neurosurg. 2010;113(Suppl):160–7.
Nurmikko TJ. Pathophysiology of MS-related trigeminal neuralgia. Pain. 2009;143(3):165–6.
Minagar A, Sheremata WA. Glossopharyngeal neuralgia and MS. Neurology. 2000;54(6):1368–70.
Al-Araji AH, Oger J. Reappraisal of Lhermitte’s sign in multiple sclerosis. Mult Scler. 2005;11(4):398–402.
Rudick R, Goodkin D. Multiple sclerosis therapeutics. London: Martin Dunitz Ltd.; 1999.
Hemmett L, et al. What drives quality of life in multiple sclerosis? QJM. 2004;97(10):671–6.
Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci. 2008;9(6):453–66.
Betts CD, D’Mellow MT, Fowler CJ. Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1993;56(3):245–50.
Fowler CJ, et al. A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2009;80(5):470–7.
de Seze M, et al. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler. 2007;13(7):915–28.
Khan F, et al. A randomised controlled trial: outcomes of bladder rehabilitation in persons with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2010;81(9):1033–8.
O’Riordan JI, et al. Do alpha-blockers have a role in lower urinary tract dysfunction in multiple sclerosis? J Urol. 1995;153(4):1114–6.
Prasad RS, Smith SJ, Wright H. Lower abdominal pressure versus external bladder stimulation to aid bladder emptying in multiple sclerosis: a randomized controlled study. Clin Rehabil. 2003;17(1):42–7.
McConnell JD, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387–98.
National Institute for Health and Clinical Excellence. Infection control. Prevention of healthcare-associated infection in primary and community care. London: National Institute for Health and Clinical Excellence; 2003.
Lekka E, Lee LK. Successful treatment with intradetrusor Botulinum-A toxin for urethral urinary leakage (catheter bypassing) in patients with end-staged multiple sclerosis and indwelling suprapubic catheters. Eur Urol. 2006;50(4):806–9; discussion 809–10.
Ethans KD, et al. Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. J Spinal Cord Med. 2004;27(3):214–8.
Gajewski JB, Awad SA. Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia. J Urol. 1986;135(5):966–8.
Amend B, et al. Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol. 2008;53(5):1021–8.
Weese DL, et al. Intravesical oxybutynin chloride: experience with 42 patients. Urology. 1993;41(6):527–30.
Fader M, et al. Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial. J Urol. 2007;177(1):208–13; discussion 213.
Herschorn S, et al. Efficacy of botulinum toxin a injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol. 2011;185(6):2229–35.
Khan S, et al. Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis. J Urol. 2011;185(4):1344–9.
Bosma R, et al. Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a meta-analysis. Acta Neurol Scand. 2005;112(1):1–5.
British National Formulary 61. London: BMJ Group and Pharma Press; 2011.
Reynard JM, et al. A novel therapy for nocturnal polyuria: a double-blind randomized trial of frusemide against placebo. Br J Urol. 1998;81(2):215–8.
Freeman RM, et al. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct. 2006;17(6):636–41.
Brady CM, et al. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler. 2004;10(4):425–33.
Kavia RB, et al. Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler. 2010;16(11):1349–59.
Ruggieri Sr MR. Cannabinoids: potential targets for bladder dysfunction. Handb Exp Pharmacol. 2011;202:425–51.
Wiart L, et al. The effects of capsaicin on the neurogenic hyperreflexic detrusor. A double blind placebo controlled study in patients with spinal cord disease. Preliminary results. Spinal Cord. 1998;36(2):95–9.
Kim JH, et al. Intravesical resiniferatoxin for refractory detrusor hyperreflexia: a multicenter, blinded, randomized, placebo-controlled trial. J Spinal Cord Med. 2003;26(4):358–63.
Marinkovic SP, Gillen LM. Sacral neuromodulation for multiple sclerosis patients with urinary retention and clean intermittent catheterization. Int Urogynecol J Pelvic Floor Dysfunct. 2010;21(2):223–8.
Tjon Eng Soe SH, et al. Multiple sclerosis patients with bladder dysfunction have decreased symptoms after electro-acupuncture. Mult Scler. 2009;15(11):1376–7.
Kabay S, et al. The clinical and urodynamic results of a 3-month percutaneous posterior tibial nerve stimulation treatment in patients with multiple sclerosis-related neurogenic bladder dysfunction. Neurourol Urodyn. 2009;28(8):964–8.
Fjorback MV, et al. Event driven electrical stimulation of the dorsal penile/clitoral nerve for management of neurogenic detrusor overactivity in multiple sclerosis. Neurourol Urodyn. 2006;25(4):349–55.
Delong J, Tighiouart H, Stoffel J. Urinary diversion/reconstruction for cases of catheter intolerant secondary progressive multiple sclerosis with refractory urinary symptoms. J Urol. 2011;185(6):2201–6.
Betts CD, et al. Erectile dysfunction in multiple sclerosis. Associated neurological and neurophysiological deficits, and treatment of the condition. Brain. 1994;117(Pt 6):1303–10.
Zorzon M, et al. Sexual dysfunction in multiple sclerosis: a case–control study. I. Frequency and comparison of groups. Mult Scler. 1999;5(6):418–27.
Lilius HG, Valtonen EJ, Wikstrom J. Sexual problems in patients suffering from multiple sclerosis. J Chronic Dis. 1976;29(10):643–7.
O’Sullivan SS, Hardiman O. Detection rates of sexual dysfunction amongst patients with multiple sclerosis in an outpatient setting – can this be improved? Ir Med J. 2006;99(10):304–6.
Zivadinov R, et al. Sexual dysfunction in multiple sclerosis: II. Correlation analysis. Mult Scler. 1999;5(6):428–31.
Rees PM, Fowler CJ, Maas CP. Sexual function in men and women with neurological disorders. Lancet. 2007;369(9560):512–25.
Fletcher SG, et al. Sexual dysfunction in patients with multiple sclerosis: a multidisciplinary approach to evaluation and management. Nat Clin Pract Urol. 2009;6(2):96–107.
Safarinejad MR. Evaluation of the safety and efficacy of sildenafil citrate for erectile dysfunction in men with multiple sclerosis: a double-blind, placebo controlled, randomized study. J Urol. 2009;181(1):252–8.
Fowler CJ, et al. A double blind, randomised study of sildenafil citrate for erectile dysfunction in men with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2005;76(5):700–5.
Pifarre P, et al. Sildenafil (Viagra) ameliorates clinical symptoms and neuropathology in a mouse model of multiple sclerosis. Acta Neuropathol. 2011;121(4):499–508.
Lombardi G, Macchiarella A, Del Popolo G. Efficacy and safety of tadalafil for erectile dysfunction in patients with multiple sclerosis. J Sex Med. 2010;7(6):2192–200.
DasGupta R, Fowler CJ. Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies. Drugs. 2003;63(2):153–66.
Safarinejad MR. Midodrine for the treatment of organic anejaculation but not spinal cord injury: a prospective randomized placebo-controlled double-blind clinical study. Int J Impot Res. 2009;21(4):213–20.
Dasgupta R, et al. Efficacy of sildenafil in the treatment of female sexual dysfunction due to multiple sclerosis. J Urol. 2004;171(3):1189–93; discussion 1193.
Chia YW, et al. Prevalence of bowel dysfunction in patients with multiple sclerosis and bladder dysfunction. J Neurol. 1995;242(2):105–8.
Hinds JP, Eidelman BH, Wald A. Prevalence of bowel dysfunction in multiple sclerosis. A population survey. Gastroenterology. 1990;98(6):1538–42.
Sullivan SN, Ebers GC. Gastrointestinal dysfunction in multiple sclerosis. Gastroenterology. 1983;84(6):1640.
Hennessey A, et al. Urinary, faecal and sexual dysfunction in patients with multiple sclerosis. J Neurol. 1999;246(11):1027–32.
Nortvedt MW, et al. Prevalence of bladder, bowel and sexual problems among multiple sclerosis patients two to five years after diagnosis. Mult Scler. 2007;13(1):106–12.
Wiesel PH, et al. Pathophysiology and management of bowel dysfunction in multiple sclerosis. Eur J Gastroenterol Hepatol. 2001;13(4):441–8.
Emmanuel A. Managing neurogenic bowel dysfunction. Clin Rehabil. 2010;24(6):483–8.
Muller-Lissner SA. Effect of wheat bran on weight of stool and gastrointestinal transit time: a meta analysis. Br Med J (Clin Res Ed). 1988;296(6622):615–7.
Wiesel PH, et al. Gut focused behavioural treatment (biofeedback) for constipation and faecal incontinence in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2000;69(2):240–3.
McClurg D, et al. Abdominal massage for the alleviation of constipation symptoms in people with multiple sclerosis: a randomized controlled feasibility study. Mult Scler. 2011;17(2):223–33.
House JG, Stiens SA. Pharmacologically initiated defecation for persons with spinal cord injury: effectiveness of three agents. Arch Phys Med Rehabil. 1997;78(10):1062–5.
Gill KP, et al. Defecography in multiple sclerosis patients with severe constipation. Radiology. 1994;191(2):553–6.
Emmanuel A. Review of the efficacy and safety of transanal irrigation for neurogenic bowel dysfunction. Spinal Cord. 2010;48(9):664–73.
Preziosi G, Emmanuel A. Neurogenic bowel dysfunction: pathophysiology, clinical manifestations and treatment. Expert Rev Gastroenterol Hepatol. 2009;3(4):417–23.
Randell N, et al. Does a colostomy alter quality of life in patients with spinal cord injury? A controlled study. Spinal Cord. 2001;39(5):279–82.
Swingler RJ, Compston DA. The morbidity of multiple sclerosis. Q J Med. 1992;83(300):325–37.
Alusi SH, et al. A study of tremor in multiple sclerosis. Brain. 2001;124(Pt 4):720–30.
Pittock SJ, et al. Prevalence of tremor in multiple sclerosis and associated disability in the Olmsted County population. Mov Disord. 2004;19(12):1482–5.
Koch M, et al. Tremor in multiple sclerosis. J Neurol. 2007;254(2):133–45.
Sandyk R, Dann LC. Weak electromagnetic fields attenuate tremor in multiple sclerosis. Int J Neurosci. 1994;79(3–4):199–212.
Dahlin-Webb SR. A weighted wrist cuff. Am J Occup Ther. 1986;40(5):363–4.
Aisen ML, et al. The effect of mechanical damping loads on disabling action tremor. Neurology. 1993;43(7):1346–50.
Armutlu K, Karabudak R, Nurlu G. Physiotherapy approaches in the treatment of ataxic multiple sclerosis: a pilot study. Neurorehabil Neural Repair. 2001;15(3):203–11.
Feys P, et al. Assistive technology to improve PC interaction for people with intention tremor. J Rehabil Res Dev. 2001;38(2):235–43.
Vergaro E, et al. Adaptive robot training for the treatment of incoordination in Multiple Sclerosis. J Neuroeng Rehabil. 2010;7:37.
Mills RJ, Yap L, Young CA. Treatment for ataxia in multiple sclerosis. Cochrane Database Syst Rev. 2007;(1):CD005029.
Henkin Y, Herishanu YO. Primidone as a treatment for cerebellar tremor in multiple sclerosis – two case reports. Isr J Med Sci. 1989;25(12):720–1.
Aisen ML, et al. Glutethimide treatment of disabling action tremor in patients with multiple sclerosis and traumatic brain injury. Arch Neurol. 1991;48(5):513–5.
Weiss N, et al. Attenuation of cerebellar tremor with implantation of an intrathecal baclofen pump: the role of gamma-aminobutyric acidergic pathways. Case report. J Neurosurg. 2003;99(4):768–71.
Schroeder A, et al. Successful treatment of cerebellar ataxia and tremor in multiple sclerosis with topiramate: a case report. Clin Neuropharmacol. 2010;33(6):317–8.
Sabra AF, et al. Treatment of action tremor in multiple sclerosis with isoniazid. Neurology. 1982;32(8):912–3.
Duquette P, Pleines J, du Souich P. Isoniazid for tremor in multiple sclerosis: a controlled trial. Neurology. 1985;35(12):1772–5.
Morrow J, et al. Isoniazid and action tremor in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1985;48(3):282–3.
Francis DA, Grundy D, Heron JR. The response to isoniazid of action tremor in multiple sclerosis and its assessment using polarised light goniometry. J Neurol Neurosurg Psychiatry. 1986;49(1):87–9.
Koller WC. Pharmacologic trials in the treatment of cerebellar tremor. Arch Neurol. 1984;41(3):280–1.
Feys P, et al. The effect of levetiracetam on tremor severity and functionality in patients with multiple sclerosis. Mult Scler. 2009;15(3):371–8.
Monaca-Charley C, et al. Double-blind crossover study with dolasetron mesilate, a 5-HT3 receptor antagonist in cerebellar syndrome secondary to multiple sclerosis. J Neurol. 2003;250(10):1190–4.
Hallett M, et al. Controlled trial of isoniazid therapy for severe postural cerebellar tremor in multiple sclerosis. Neurology. 1985;35(9):1374–7.
Bozek CB, et al. A controlled trial of isoniazid therapy for action tremor in multiple sclerosis. J Neurol. 1987;234(1):36–9.
Sechi GP, et al. Treatment of cerebellar tremors with carbamazepine: a controlled trial with long-term follow-up. Neurology. 1989;39(8):1113–5.
Rice GP, et al. Ondansetron, a 5-HT3 antagonist, improves cerebellar tremor. J Neurol Neurosurg Psychiatry. 1997;62(3):282–4.
Zajicek J, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003;362(9395):1517–26.
Fox P, et al. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology. 2004;62(7):1105–9.
Wade DT, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004;10(4):434–41.
Yap L, Kouyialis A, Varma TR. Stereotactic neurosurgery for disabling tremor in multiple sclerosis: thalamotomy or deep brain stimulation? Br J Neurosurg. 2007;21(4):349–54.
Johnson RD, et al. Perioperative seizures following deep brain stimulation in patients with multiple sclerosis. Br J Neurosurg. 2010;24(3):289–90.
Jahanshahi M, et al. Effects on cognition of stereotactic lesional surgery for the treatment of tremor in multiple sclerosis. Behav Neurol. 2008;20(1–2):1–9.
Timmermann L, et al. Deep brain stimulation for tremor in multiple sclerosis: consensus recommendations of the German Deep Brain Stimulation Association. Nervenarzt. 2009;80(6):673–7.
Figved N, et al. Caregiver burden in multiple sclerosis: the impact of neuropsychiatric symptoms. J Neurol Neurosurg Psychiatry. 2007;78(10):1097–102.
Patten SB, et al. Major depression in multiple sclerosis: a population-based perspective. Neurology. 2003;61(11):1524–7.
Chwastiak L, et al. Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. Am J Psychiatry. 2002;159(11):1862–8.
Harel Y, Barak Y, Achiron A. Dysregulation of affect in multiple sclerosis: new phenomenological approach. Psychiatry Clin Neurosci. 2007;61(1):94–8.
Feinstein A. Mood disorders in multiple sclerosis and the effects on cognition. J Neurol Sci. 2006;245(1–2):63–6.
Demaree HA, Gaudino E, DeLuca J. The relationship between depressive symptoms and cognitive dysfunction in multiple sclerosis. Cogn Neuropsychiatry. 2003;8(3):161–71.
Figved N, et al. Relationship of cognitive impairment to psychiatric symptoms in multiple sclerosis. Mult Scler. 2008;14(8):1084–90.
McGuigan C, Hutchinson M. Unrecognised symptoms of depression in a community-based population with multiple sclerosis. J Neurol. 2006;253(2):219–23.
Lincoln NB, et al. Evaluation of an adjustment group for people with multiple sclerosis and low mood: a randomized controlled trial. Mult Scler. 2011;17(10):1250–7.
Rigby SA, Thornton EW, Young CA. A randomized group intervention trial to enhance mood and self-efficacy in people with multiple sclerosis. Br J Health Psychol. 2008;13(Pt 4):619–31.
Dennison L, Moss-Morris R. Cognitive-behavioral therapy: what benefits can it offer people with multiple sclerosis? Expert Rev Neurother. 2010;10(9):1383–90.
Thomas PW, et al. Psychological interventions for multiple sclerosis. Cochrane Database Syst Rev. 2006;(1):CD004431.
Koch MW, et al. Pharmacologic treatment of depression in multiple sclerosis. Cochrane Database Syst Rev. 2011;(2):CD007295.
Price A, et al. Antidepressants for the treatment of depression in neurological disorders: a systematic review and meta-analysis of randomised controlled trials. J Neurol Neurosurg Psychiatry. 2011;82(8):914–23.
Patten SB, Svenson LW, Metz LM. Psychotic disorders in MS: population-based evidence of an association. Neurology. 2005;65(7):1123–5.
Surridge D. An investigation into some psychiatric aspects of multiple sclerosis. Br J Psychiatry. 1969;115(524):749–64.
Kosmidis MH, et al. Psychotic features associated with multiple sclerosis. Int Rev Psychiatry. 2010;22(1):55–66.
Sechi GP, et al. Dexamethasone-induced schizoaffective-like state in multiple sclerosis: prophylaxis and treatment with carbamazepine. Clin Neuropharmacol. 1987;10(5):453–7.
Minden SL, Orav J, Schildkraut JJ. Hypomanic reactions to ACTH and prednisone treatment for multiple sclerosis. Neurology. 1988;38(10):1631–4.
Goeb JL, et al. Acute delirium, delusion, and depression during IFN-beta-1a therapy for multiple sclerosis: a case report. Clin Neuropharmacol. 2003;26(1):5–7.
Manfredi G, et al. Persistent interferon-ss-1b-induced psychosis in a patient with multiple sclerosis. Psychiatry Clin Neurosci. 2010;64(5):584–6.
Feinstein A, du Boulay G, Ron MA. Psychotic illness in multiple sclerosis. A clinical and magnetic resonance imaging study. Br J Psychiatry. 1992;161:680–5.
Chong SA, Ko SM. Clozapine treatment of psychosis associated with multiple sclerosis. Can J Psychiatry. 1997;42(1):90–1.
Safferman AZ, et al. The use of clozapine in neurologic disorders. J Clin Psychiatry. 1994;55(Suppl B):98–101.
Hussain A, Belderbos S. Risperidone depot in the treatment of psychosis associated with multiple sclerosis – a case report. J Psychopharmacol. 2008;22(8):925–6.
Davids E, Hartwig U, Gastpar M. Antipsychotic treatment of psychosis associated with multiple sclerosis. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(4):743–4.
Schiffer RB, Wineman NM, Weitkamp LR. Association between bipolar affective disorder and multiple sclerosis. Am J Psychiatry. 1986;143(1):94–5.
Paparrigopoulos T, et al. The neuropsychiatry of multiple sclerosis: focus on disorders of mood, affect and behaviour. Int Rev Psychiatry. 2010;22(1):14–21.
Feinstein A, et al. Prevalence and neurobehavioral correlates of pathological laughing and crying in multiple sclerosis. Arch Neurol. 1997;54(9):1116–21.
Pioro EP, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol. 2010;68(5):693–702.
Panitch HS, et al. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol. 2006;59(5):780–7.
Schiffer RB, Herndon RM, Rudick RA. Treatment of pathologic laughing and weeping with amitriptyline. N Engl J Med. 1985;312(23):1480–2.
Iannaccone S, Ferini-Strambi L. Pharmacologic treatment of emotional lability. Clin Neuropharmacol. 1996;19(6):532–5.
Nahas Z, et al. Rapid response of emotional incontinence to selective serotonin reuptake inhibitors. J Neuropsychiatry Clin Neurosci. 1998;10(4):453–5.
Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol. 2008;7(12):1139–51.
Portaccio E, et al. Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis. Neurology. 2009;73(7):498–503.
Potagas C, et al. Cognitive impairment in different MS subtypes and clinically isolated syndromes. J Neurol Sci. 2008;267(1–2):100–6.
Amato MP, et al. Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol. 2001;58(10):1602–6.
Denney DR, Sworowski LA, Lynch SG. Cognitive impairment in three subtypes of multiple sclerosis. Arch Clin Neuropsychol. 2005;20(8):967–81.
Rao SM, et al. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology. 1991;41(5):692–6.
Jennekens-Schinkel A, et al. Cognition in patients with multiple sclerosis after four years. J Neurol Sci. 1990;99(2–3):229–47.
Kujala P, Portin R, Ruutiainen J. The progress of cognitive decline in multiple sclerosis. A controlled 3-year follow-up. Brain. 1997;120(Pt 2):289–97.
Fischer JS, et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol. 2000;48(6):885–92.
Patti F, et al. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. Mult Scler. 2010;16(1):68–77.
Pliskin NH, et al. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology. 1996;47(6):1463–8.
Flechter S, et al. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study. Isr Med Assoc J. 2007;9(6):457–9.
Kappos L, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007;370(9585):389–97.
Mattioli F, Stampatori C, Capra R. The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study. Neurol Sci. 2011;32(1):83–8.
D’Intino G, et al. Cognitive deficit associated with cholinergic and nerve growth factor down-regulation in experimental allergic encephalomyelitis in rats. Proc Natl Acad Sci USA. 2005;102(8):3070–5.
Krupp LB, et al. Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. Neurology. 2011;76(17):1500–7.
Shaygannejad V, et al. Effects of rivastigmine on memory and cognition in multiple sclerosis. Can J Neurol Sci. 2008;35(4):476–81.
Villoslada P, et al. Memantine induces reversible neurologic impairment in patients with MS. Neurology. 2009;72(19):1630–3.
Lovera JF, et al. Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. Mult Scler. 2010;16(6):715–23.
Geisler MW, et al. The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Arch Neurol. 1996;53(2):185–8.
Lovera J, et al. Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial. Mult Scler. 2007;13(3):376–85.
Morrow SA, et al. The effects of L-amphetamine sulfate on cognition in MS patients: results of a randomized controlled trial. J Neurol. 2009;256(7):1095–102.
Oleen-Burkey M, Hadjimichael O, Vollmer T. Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey. Health Qual Life Outcomes. 2008;6:100.
Krupp L. Fatigue is intrinsic to multiple sclerosis (MS) and is the most commonly reported symptom of the disease. Mult Scler. 2006;12(4):367–8.
Lerdal A, et al. A prospective study of patterns of fatigue in multiple sclerosis. Eur J Neurol. 2007;14(12):1338–43.
Smith MM, Arnett PA. Factors related to employment status changes in individuals with multiple sclerosis. Mult Scler. 2005;11(5):602–9.
Judica E, et al. Impact of fatigue on the efficacy of rehabilitation in multiple sclerosis. J Neurol. 2011;258(5):835–9.
Veauthier C, et al. Fatigue in multiple sclerosis is closely related to sleep disorders: a polysomnographic cross-sectional study. Mult Scler. 2011;17(5):613–22.
Kaminska M, et al. Sleep disorders and fatigue in multiple sclerosis: evidence for association and interaction. J Neurol Sci. 2011;302(1–2):7–13.
Braley TJ, Chervin RD. Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment. Sleep. 2010;33(8):1061–7.
Schwid SR, et al. A randomized controlled study of the acute and chronic effects of cooling therapy for MS. Neurology. 2003;60(12):1955–60.
van Kessel K, et al. A randomized controlled trial of cognitive behavior therapy for multiple sclerosis fatigue. Psychosom Med. 2008;70(2):205–13.
Thomas PW, et al. Multi-centre parallel arm randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based cognitive behavioural approach to managing fatigue in people with multiple sclerosis. BMC Neurol. 2010;10:43.
Piatkowski J, Kern S, Ziemssen T. Effect of BEMER magnetic field therapy on the level of fatigue in patients with multiple sclerosis: a randomized, double-blind controlled trial. J Altern Complement Med. 2009;15(5):507–11.
Carvalho ML, et al. A randomized placebo-controlled cross-over study using a low frequency magnetic field in the treatment of fatigue in multiple sclerosis. Mult Scler. 2012;18(1):82–9.
Metz LM, et al. The effect of immunomodulatory treatment on multiple sclerosis fatigue. J Neurol Neurosurg Psychiatry. 2004;75(7):1045–7.
Putzki N, et al. Multiple sclerosis associated fatigue during natalizumab treatment. J Neurol Sci. 2009;285(1–2):109–13.
Yildiz M, Tettenborn B, Putzki N. Multiple sclerosis-associated fatigue during disease-modifying treatment with natalizumab, interferon-beta and glatiramer acetate. Eur Neurol. 2011;65(4):231–2.
Multiple Sclerosis Council for Clinical Practice Guidelines. Fatigue and multiple sclerosis. Evidence-based management strategies for fatigue in multiple sclerosis. Washington: Paralyzed Veterans of America; 1998.
Branas P, et al. Treatments for fatigue in multiple sclerosis: a rapid and systematic review. Health Technol Assess. 2000;4(27):1–61.
Pucci E, et al. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2007;(1):CD002818.
Taus C, et al. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2003;(2):CD002818.
Lange R, et al. Modafinil effects in multiple sclerosis patients with fatigue. J Neurol. 2009;256(4):645–50.
Moller F, et al. HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis. Mult Scler. 2011;17(8):1002–9.
Weinshenker BG, et al. A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology. 1992;42(8):1468–71.
Krupp LB, et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology. 1995;45(11):1956–61.
Goodman AD, et al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler. 2007;13(3):357–68.
Solari JJ, Pozzi AG, Ceballos NR. Seasonal changes in the activity of cytochrome P450(C17) from the testis of Bufo arenarum. J Comp Physiol B. 2002;172(8):685–90.
Sheean GL, et al. An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis. Brain. 1998;121(Pt 5):967–75.
Rossini PM, et al. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult Scler. 2001;7(6):354–8.
Flet L, et al. 3,4-diaminopyridine safety in clinical practice: an observational, retrospective cohort study. J Neurol. 2010;257(6):937–46.
Tejani AM, et al. Carnitine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2010;(2):CD007280.
Tomassini V, et al. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. J Neurol Sci. 2004;218(1–2):103–8.
Kim E, et al. American ginseng does not improve fatigue in multiple sclerosis: a single center randomized double-blind placebo-controlled crossover pilot study. Mult Scler. 2011;17(12):1523–6.
Caminero A, Bartolome M. Sleep disturbances in multiple sclerosis. J Neurol Sci. 2011;309(1–2):86–91.
Brass SD, et al. Sleep disorders in patients with multiple sclerosis. Sleep Med Rev. 2010;14(2):121–9.
Newman NJ. Multiple sclerosis and related demyelinating diseases. In: Miller NR, Newman NJ, editors. Walsh and Hoyt’s clinical neuro-ophthalmology. Baltimore: Williams and Wilkins; 1998. p. 5539–76.
Ganley JP. Uveitis and multiple sclerosis: an overview. In: Saari KM, editor. Uveitis update. Amsterdam: Excerpta Medica; 1984. p. 345–9.
Rushton D, Cox N. A new optical treatment for oscillopsia. J Neurol Neurosurg Psychiatry. 1987;50(4):411–5.
Starck M, et al. Acquired pendular nystagmus in multiple sclerosis: an examiner-blind cross-over treatment study of memantine and gabapentin. J Neurol. 2010;257(3):322–7.
Leigh RJ, et al. Crossover trial of gabapentin and memantine as treatment for acquired nystagmus. Ann Neurol. 2010;67(5):676–80.
Strupp M, et al. Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study. Neurology. 2003;61(2):165–70.
Kalla R, et al. 4-aminopyridine improves downbeat nystagmus, smooth pursuit, and VOR gain. Neurology. 2004;62(7):1228–9.
Kalla R, et al. Comparison of 10-mg Doses of 4-Aminopyridine and 3,4-Diaminopyridine for the Treatment of Downbeat Nystagmus. J Neuroophthalmol. 2011;31(4):320–5.
Averbuch-Heller L. Acquired nystagmus. Curr Treat Options Neurol. 1999;1(1):68–73.
Menon GJ, Thaller VT. Therapeutic external ophthalmoplegia with bilateral retrobulbar botulinum toxin- an effective treatment for acquired nystagmus with oscillopsia. Eye (Lond). 2002;16(6):804–6.
Ruben ST, et al. The use of botulinum toxin for treatment of acquired nystagmus and oscillopsia. Ophthalmology. 1994;101(4):783–7.
Adams WE, Leavitt JA, Holmes JM. Strabismus surgery for internuclear ophthalmoplegia with exotropia in multiple sclerosis. J AAPOS. 2009;13(1):13–5.
Thomas FJ, Wiles CM. Dysphagia and nutritional status in multiple sclerosis. J Neurol. 1999;246(8):677–82.
Giusti A, Giambuzzi M. Management of dysphagia in patients affected by multiple sclerosis: state of the art. Neurol Sci. 2008;29 Suppl 4:S364–6.
Alfonsi E, et al. An electrophysiological approach to the diagnosis of neurogenic dysphagia: implications for botulinum toxin treatment. J Neurol Neurosurg Psychiatry. 2010;81(1):54–60.
Restivo DA, et al. Botulinum toxin improves dysphagia associated with multiple sclerosis. Eur J Neurol. 2011;18(3):486–90.
Marrosu F, et al. Vagal nerve stimulation improves cerebellar tremor and dysphagia in multiple sclerosis. Mult Scler. 2007;13(9):1200–2.
Beukelman DR, Kraft GH, Freal J. Expressive communication disorders in persons with multiple sclerosis: a survey. Arch Phys Med Rehabil. 1985;66(10):675–7.
Hartelius L, Svensson P. Speech and swallowing symptoms associated with Parkinson’s disease and multiple sclerosis: a survey. Folia Phoniatr Logop. 1994;46(1):9–17.
Hartelius L, Runmarker B, Andersen O. Prevalence and characteristics of dysarthria in a multiple-sclerosis incidence cohort: relation to neurological data. Folia Phoniatr Logop. 2000;52(4):160–77.
Darley FL, Brown JR, Goldstein NP. Dysarthria in multiple sclerosis. J Speech Hear Res. 1972;15(2):229–45.
Parker M, et al. Automatic speech recognition and training for severely dysarthric users of assistive technology: the STARDUST project. Clin Linguist Phon. 2006;20(2–3):149–56.
Blanco Y, et al. Midbrain lesions and paroxysmal dysarthria in multiple sclerosis. Mult Scler. 2008;14(5):694–7.
Valentino P, et al. Lamotrigine therapy for paroxysmal dysarthria caused by multiple sclerosis: a case report. J Neurol. 2011;258(7):1349–50.
Voiculescu V, Pruskauer-Apostol B, Alecu C. Treatment with acetazolamide of brain-stem and spinal paroxysmal disturbances in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1975;38(2):191–3.
Lensch E, Jost WH. Autonomic disorders in multiple sclerosis. Autoimmune Dis. 2011;2011:803841.
Davis SL, et al. Thermoregulation in multiple sclerosis. J Appl Physiol. 2010;109(5):1531–7.
Higginson IJ, et al. Symptom prevalence and severity in people severely affected by multiple sclerosis. J Palliat Care. 2006;22(3):158–65.
O’Brien T. Neurodegenerative disease. In: Addington-Hall JM, Higginson IJ, editors. Palliative care for non-cancer patients. Oxford: Oxford University Press; 2001. p. 44–55.
Kumpfel T, et al. Palliative care in patients with severe multiple sclerosis: two case reports and a survey among German MS neurologists. Palliat Med. 2007;21(2):109–14.
Higginson IJ, et al. Is short-term palliative care cost-effective in multiple sclerosis? A randomized phase II trial. J Pain Symptom Manage. 2009;38(6):816–26.
Edmonds P, et al. Palliative care for people severely affected by multiple sclerosis: evaluation of a novel palliative care service. Mult Scler. 2010;16(5):627–36.
Golla H, et al. Unmet needs of severely affected multiple sclerosis patients: the health professionals’ view. Palliat Med. 2012;26(2):139–51.
Department of Health Long-term Conditions NSF Team. The National Service Framework for Long-term Conditions. London: DH; 2005. Department of Health, UK Government.
Guideline Development Group. Longterm neurological conditions: management at the interface between neurology, rehabilitation and palliative care. London: Royal College of Physicians; 2008.
Campbell CW, Jones EJ, Merrills J. Palliative and end-of-life care in advanced Parkinson’s disease and multiple sclerosis. Clin Med. 2010;10(3):290–2.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag London
About this chapter
Cite this chapter
Rice, C.M., Wilkins, A. (2013). Symptomatic Treatment for Progressive Multiple Sclerosis. In: Wilkins, A. (eds) Progressive Multiple Sclerosis. Springer, London. https://doi.org/10.1007/978-1-4471-2395-8_8
Download citation
DOI: https://doi.org/10.1007/978-1-4471-2395-8_8
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-2394-1
Online ISBN: 978-1-4471-2395-8
eBook Packages: MedicineMedicine (R0)